Aspira Women’s Health (NASDAQ:AWH) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note released on Tuesday. The firm issued a hold rating on the stock.

Aspira Women’s Health Trading Up 1.8 %

Shares of AWH opened at $0.72 on Tuesday. The company’s 50 day simple moving average is $0.79 and its 200-day simple moving average is $1.00. Aspira Women’s Health has a 12-month low of $0.67 and a 12-month high of $5.65. The firm has a market cap of $11.96 million, a PE ratio of -0.60 and a beta of 1.39.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co purchased a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned approximately 0.19% of Aspira Women’s Health as of its most recent SEC filing. 12.19% of the stock is owned by hedge funds and other institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.